Andreas Halvorsen: portfolio of Viking Global Investors

Andreas Halvorsen leads Viking Global Investors, a hedge fund that analyzes stocks worldwide and combines long and short positions.

Source: 13F filing with the US Securities and Exchange Commission dated May 15, 2025. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q1 2025. Go to the latest filing (Q3 2026)

31.5B USDQ1 2025
Total value of stock positions
31.5B USD
Positions
91
Share of the ten largest
33.6%

The ten largest positions Q1 2025

  1. U.S. Bancorp 4.7%▲ +42.6%
  2. Charles Schwab Corporation 4.4%▲ +20.9%
  3. Bank of America 4.3%▲ +30.3%
  4. UnitedHealth Group 3.6%▲ +12.5%
  5. Intuit 3.3%▼ −0.7%
  6. Fortive 3.0%▼ −1.8%
  7. Meta Platforms 2.7%new
  8. Capital One 2.6%new
  9. Taiwan Semiconductor Manufacturing (ADR) 2.6%▲ +19.6%
  10. Api Group Corp 2.4%unchanged
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 38.5B USD).
Choose a quarter (54 filings)

All positions Q1 2025

Positions Q1 2025 per 13F filing, 50 of 91
Symbol Weight Shares Reported value Change Held since
AMZN Amazon 1.6% 2,721,710 517.8M USD +4.1% increased Q2 2015 40 quarters
Bridgebio Pharma Inc 2.4% 22,055,375 762.5M USD −12.2% reduced Q2 2019 24 quarters
Adaptive Biotechnologies Cor 0.7% 29,993,708 222.9M USD unchanged Q2 2019 24 quarters
FTV Fortive 3.0% 12,950,122 947.7M USD −1.8% reduced Q3 2019 23 quarters
Api Group Corp 2.4% 21,537,518 770.2M USD unchanged Q2 2020 20 quarters
Royalty Pharma PLC 1.0% 10,563,939 328.9M USD −13.5% reduced Q2 2020 20 quarters
Pharvaris N V 0.2% 3,653,310 57.4M USD unchanged Q1 2021 17 quarters
Edgewise Therapeutics Inc < 0.1% 490,035 10.8M USD −60.0% reduced Q1 2021 17 quarters
Rallybio Corp < 0.1% 4,194,777 2.7M USD unchanged Q3 2021 15 quarters
Biomarin Pharmaceutical Inc 2.4% 10,800,059 763.5M USD +2.8% increased Q4 2021 14 quarters
Roivant Sciences Ltd 1.5% 46,013,752 464.3M USD −3.8% reduced Q4 2021 14 quarters
PGR Progressive Corporation 1.0% 1,068,406 302.4M USD −50.8% reduced Q1 2022 13 quarters
Pepgen Inc < 0.1% 1,482,434 2.1M USD unchanged Q2 2022 12 quarters
Trevi Therapeutics Inc < 0.1% 3,227,792 20.3M USD −26.6% reduced Q3 2022 11 quarters
CSX CSX Corporation 1.6% 17,068,769 502.3M USD +16.3% increased Q4 2022 10 quarters
Newamsterdam Pharma Company 0.5% 6,978,534 142.9M USD unchanged Q4 2022 10 quarters
PM Philip Morris International 1.6% 3,213,460 510.1M USD −36.8% reduced Q2 2023 8 quarters
USB U.S. Bancorp 4.7% 34,863,502 1.5B USD +42.6% increased Q4 2023 6 quarters
TMUS T-Mobile US 1.3% 1,565,894 417.6M USD +156.5% increased Q4 2023 6 quarters
HCA HCA Healthcare 1.3% 1,181,360 408.2M USD +6.4% increased Q4 2023 6 quarters
Regal Rexnord Corporation 1.0% 2,728,983 310.7M USD +214.9% increased Q4 2023 6 quarters
CPT Camden Property Trust 1.1% 2,788,789 341.1M USD −17.1% reduced Q1 2024 5 quarters
MSFT Microsoft 0.8% 683,918 256.7M USD −71.4% reduced Q1 2024 5 quarters
Equitable HLDGS Inc 0.5% 3,279,559 170.8M USD +329.1% increased Q1 2024 5 quarters
Integer HLDGS Corp 0.4% 1,177,273 138.9M USD +1.9% increased Q1 2024 5 quarters
Standard Biotools Inc 0.2% 58,651,170 63.3M USD unchanged Q1 2024 5 quarters
Oric Pharmaceuticals Inc 0.1% 6,572,700 36.7M USD – Q1 2024 5 quarters
Immunovant Inc < 0.1% 1,114,827 19.1M USD −20.8% reduced Q1 2024 5 quarters
INTU Intuit 3.3% 1,706,420 1.0B USD −0.7% reduced Q2 2024 4 quarters
NVDA Nvidia 2.3% 6,543,107 709.1M USD +222.0% increased Q2 2024 4 quarters
NFLX Netflix 2.2% 749,431 698.9M USD +49.2% increased Q2 2024 4 quarters
CVNA Carvana 1.7% 2,553,861 534.0M USD +192.3% increased Q2 2024 4 quarters
JPM JPMorgan Chase 1.7% 2,171,648 532.7M USD −70.9% reduced Q2 2024 4 quarters
ALL Allstate 1.1% 1,703,403 352.7M USD −12.1% reduced Q2 2024 4 quarters
DASH DoorDash 1.1% 1,858,037 339.6M USD −62.5% reduced Q2 2024 4 quarters
SHW Sherwin-Williams 1.1% 972,230 339.5M USD +57.3% increased Q2 2024 4 quarters
Spotify Technology S A 0.3% 192,877 106.1M USD −87.5% reduced Q2 2024 4 quarters
Inhibrx Biosciences Inc < 0.1% 1,787,705 25.0M USD unchanged Q2 2024 4 quarters
SCHW Charles Schwab Corporation 4.4% 17,716,717 1.4B USD +20.9% increased Q3 2024 3 quarters
BAC Bank of America 4.3% 32,199,070 1.3B USD +30.3% increased Q3 2024 3 quarters
V Visa Inc. 2.4% 2,125,091 744.8M USD −39.2% reduced Q3 2024 3 quarters
Flutter Entmt PLC 1.8% 2,554,206 565.9M USD +36.7% increased Q3 2024 3 quarters
SNPS Synopsys 1.0% 703,912 301.9M USD −2.4% reduced Q3 2024 3 quarters
BSX Boston Scientific 0.8% 2,376,764 239.8M USD +9.4% increased Q3 2024 3 quarters
Teva Pharmaceutical Inds Ltd 0.5% 10,125,478 155.6M USD +55.7% increased Q3 2024 3 quarters
Transunion 0.4% 1,336,984 111.0M USD −67.4% reduced Q3 2024 3 quarters
Biontech SE 0.3% 879,972 80.1M USD −6.5% reduced Q3 2024 3 quarters
ADSK Autodesk 0.3% 304,494 79.7M USD −59.8% reduced Q3 2024 3 quarters
Ginkgo Bioworks Holdings Inc < 0.1% 3,577,128 20.4M USD unchanged Q3 2024 3 quarters
MET MetLife < 0.1% 84,312 6.8M USD −98.6% reduced Q3 2024 3 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Show more (up to 500) Shown: the 50 longest-held of 91 positions.

Breakdown by sector

  • Financials 26.2%
  • Technology 11.5%
  • Consumer Discretionary 11.4%
  • Health Care 7.1%
  • Industrials 6.4%
  • Communication Services 6.3%
  • Real Estate 2.3%
  • Consumer Staples 2.2%
  • Materials 1.1%
  • not in our coverage 25.6%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close